Phospho-BAD (S155) Antibody

What is BAD protein and what role does phosphorylation at S155 play?

BAD (Bcl2-associated agonist of cell death) is a proapoptotic member of the Bcl-2 family that promotes cell death by displacing Bax from binding to Bcl-2 and Bcl-xL. BAD has several phosphorylation sites, including S75, S99, S112, S136, and S155, each playing distinct roles in regulating its function .

Phosphorylation at S155 specifically:

• Occurs within the BH3 domain by Protein Kinase A (PKA)

• Plays a critical role in blocking the dimerization of BAD and Bcl-xL

• Directly inhibits BAD's proapoptotic activity

• Contributes to cell survival signaling pathways

Notably, while phosphorylation at S99 or S75 promotes heterodimerization with 14-3-3 proteins, phosphorylation at S155 directly disrupts the BAD-Bcl-xL interaction, representing a distinct regulatory mechanism .

How do Phospho-BAD (S155) antibodies specifically detect phosphorylated BAD?

Phospho-BAD (S155) antibodies are designed to recognize BAD protein only when phosphorylated at serine 155, using several approaches to ensure specificity:

• Immunogen design: These antibodies are typically produced against synthetic phosphopeptides derived from the human BAD sequence around the phosphorylation site of Ser155 (amino acid range 119-168) .

• Affinity purification: The most effective antibody production procedure involves:

  • Removing antibodies that bind to dephosphorylated antigen using a dephospho-peptide affinity column

  • Positive selection of the flow-through on a phospho-peptide column

• Specificity testing: The antibodies undergo rigorous validation to ensure they detect only the phosphorylated form of BAD at S155, including Western blot analysis with phosphatase treatments and phospho-peptide blocking experiments .

This specificity allows researchers to monitor BAD phosphorylation status at S155 independently of other phosphorylation sites (S112, S136), providing insights into specific PKA-mediated survival pathways .

What applications are appropriate for Phospho-BAD (S155) antibodies and what are recommended dilutions?

Phospho-BAD (S155) antibodies are versatile tools applicable to multiple experimental techniques. Based on validation data, recommended applications and dilutions include:

For optimal results:

• In IHC applications, paraffin-embedded tissue sections typically require a more concentrated antibody (1:50-1:100) as demonstrated in validation studies using human breast carcinoma tissue .

• For Western blot analysis, confirming specificity is critical, especially when analyzing cells treated with PKA activators like Forskolin .

• Immunofluorescence applications may require optimization depending on fixation methods and target tissue types .

The actual working concentration should be determined by the researcher based on specific experimental conditions and sample types .

What controls should be included when working with Phospho-BAD (S155) antibodies?

Proper controls are essential when working with phosphorylation-specific antibodies. For Phospho-BAD (S155) antibodies, consider the following controls:

Positive controls:

• Cell lysates from cells treated with PKA activators (e.g., Forskolin) to induce S155 phosphorylation

• Tissues known to express phosphorylated BAD (e.g., breast carcinoma samples)

Negative controls:

• Phosphopeptide competition: Pre-incubating the antibody with the immunizing phosphopeptide should abolish specific staining

• Dephosphopeptide competition: Pre-incubation with the non-phosphorylated peptide should not affect staining

• Alkaline phosphatase treatment: Treating samples with alkaline phosphatase should eliminate antibody recognition

Validation controls:

• Western blotting should show a single band at the expected molecular weight (~23 kDa for BAD)

• For IHC, parallel sections with phospho-peptide blocking demonstrate specificity, as shown in validated breast carcinoma tissue sections

• Molecular genetic controls using site-directed mutagenesis (S155A) provide definitive evidence of specificity

Implementation of these controls ensures reliable and interpretable results when using phospho-specific BAD antibodies in research applications.

How should Phospho-BAD (S155) antibodies be stored and handled to maintain activity?

Proper storage and handling of Phospho-BAD (S155) antibodies are crucial for maintaining their specificity and activity. Based on manufacturer recommendations:

Storage conditions:

• Long-term storage: -20°C for up to one year

• Short-term/frequent use: 4°C for up to one month

Formulation considerations:

• Most commercial antibodies are supplied in PBS containing:

  • 50% glycerol (cryoprotectant)

  • 0.5% BSA (stabilizer)

  • 0.02% sodium azide (preservative)

Handling precautions:

• Avoid repeated freeze-thaw cycles, which can degrade antibody quality

• Aliquot antibodies upon first thaw if frequent use is anticipated

• Allow antibodies to reach room temperature before opening to prevent condensation

• Briefly centrifuge vials before opening to collect liquid at the bottom

Working solution preparation:

• Dilute only the amount needed for immediate use

• Prepare dilutions in appropriate buffers (typically PBS with 0.1-0.5% BSA)

• Use diluted antibodies within 24 hours for optimal results

Following these guidelines will help preserve antibody activity and ensure consistent experimental results across multiple applications .

How can you validate the specificity of Phospho-BAD (S155) antibodies in your experimental system?

Validating phosphorylation state-specific antibodies (PSSAs) requires a comprehensive approach that goes beyond standard antibody validation. For Phospho-BAD (S155) antibodies, consider these rigorous validation strategies:

Biochemical validation:

• Western blot analysis comparing stimulated vs. unstimulated samples:

  • Treat cells with PKA activators (e.g., Forskolin) to induce S155 phosphorylation

  • Compare with untreated controls

  • Verify a single band at the expected molecular weight (~23 kDa)

Peptide competition assays:

• Perform parallel experiments with:

  • Primary antibody alone

  • Primary antibody pre-incubated with phospho-S155 peptide

  • Primary antibody pre-incubated with non-phospho-S155 peptide

• Specific signal should be blocked only by the phosphopeptide

Enzymatic treatments:

• Treat duplicate samples with lambda phosphatase

• Signal should be abolished in phosphatase-treated samples

• Include phosphatase inhibitor controls to confirm specificity

Genetic validation approaches:

• Express wild-type BAD versus S155A mutant (non-phosphorylatable)

• Only wild-type BAD should show phospho-S155 signal when cells are stimulated

• This represents the gold standard for specificity validation

Cross-reactivity assessment:

• Test antibodies on samples from knockout/knockdown models

• Examine potential cross-reactivity with other phosphorylated proteins

• Evaluate signal in multiple species if cross-species reactivity is claimed

What are the key technical considerations for using Phospho-BAD (S155) antibodies in immunohistochemistry?

Successful immunohistochemical detection of phosphorylated BAD presents several technical challenges that require careful optimization:

Tissue fixation and processing:

• Phosphoepitopes are particularly labile during standard fixation

• Rapid fixation in 10% neutral buffered formalin (preferably <24 hours) helps preserve phosphorylation status

• Phosphatase inhibitors should be included in all buffers during tissue processing

Antigen retrieval optimization:

• Heat-induced epitope retrieval is typically required for FFPE tissues

• Test multiple pH conditions:

  • Citrate buffer (pH 6.0)

  • EDTA buffer (pH 8.0-9.0)

• Optimal conditions must be determined empirically for phospho-BAD (S155)

Signal amplification considerations:

• Low abundance phosphoproteins often require signal amplification

• Tyramide signal amplification (TSA) can enhance detection sensitivity

• Polymer-based detection systems often provide better results than ABC methods

Scoring and quantification approaches:

• Semi-quantitative evaluation using immunoscores should consider:

  • Staining intensity (0-4 scale)

  • Percentage of positive cells

• For research applications, a combined score based on both parameters provides more reliable assessment

Common pitfalls and troubleshooting:

• False negatives are common due to epitope lability

• Consider using positive control tissues known to express phospho-BAD (e.g., breast carcinoma)

• Comparison with Western blot results can help validate IHC findings

• The phospho-S155 epitope may be masked in protein complexes in situ

Using these approaches, researchers can reliably detect phosphorylated BAD in tissue sections while minimizing artifacts and false results .

How do the different phosphorylation sites of BAD (S112, S136, S155) interact functionally?

BAD phosphorylation at multiple serine residues creates a complex regulatory network controlling its proapoptotic activity through different but interconnected mechanisms:

Site-specific kinase regulation:

• S112: Primarily phosphorylated by p90RSK and mitochondria-anchored PKA

• S136: Major target of Akt/PKB signaling

• S155: Predominantly phosphorylated by PKA within the BH3 domain

Hierarchical phosphorylation patterns:

• Phosphorylation at S136 (by Akt) often precedes and promotes S112 phosphorylation

• S136 phosphorylation creates a docking site for 14-3-3 proteins, which facilitates subsequent phosphorylation at S112 and S155

• This sequential pattern creates a phosphorylation cascade requiring multiple survival signals

Functional consequences of multi-site phosphorylation:

• S112 and S136: Promotes binding to 14-3-3 proteins, sequestering BAD in the cytosol

• S155: Directly blocks interaction between the BH3 domain of BAD and its binding pocket in Bcl-XL

• The combined effect of these phosphorylation events provides multiple layers of apoptosis regulation

Distinct phosphorylation profiles in disease models:

• In rapamycin-treated lung cancer cells, enhanced phosphorylation occurs at S112 and S136 but not S155

• These differential phosphorylation patterns contribute to treatment resistance

• Targeting specific phosphorylation sites can synergistically enhance therapeutic efficacy

Understanding these complex interactions between phosphorylation sites provides insights into how survival and apoptotic signals are integrated at the molecular level, potentially informing therapeutic approaches targeting the BAD protein .

What are the best methods to quantify BAD phosphorylation in complex tissue samples?

Quantifying BAD phosphorylation in complex tissues requires specialized approaches to overcome challenges of heterogeneity, low abundance, and phosphoepitope lability:

Tissue-based analytical approaches:

Biochemical extraction approaches:

Computational and normalization considerations:

• For IHC quantification, use semi-quantitative immunoscoring that incorporates:

  • Staining intensity (0-4 scale)

  • Percentage of positive cells

  • Combined score calculation for statistical analysis

• Always normalize phospho-BAD to total BAD protein levels

• Consider tissue heterogeneity in interpretation of results

These methods, when properly optimized and controlled, provide reliable quantification of BAD phosphorylation status in complex tissues for both basic research and potential clinical applications .

How can phospho-BAD antibodies be used to investigate mechanisms of cell death and survival in cancer models?

Phospho-BAD antibodies provide powerful tools for investigating apoptotic regulation in cancer, enabling researchers to connect signaling pathways with cellular outcomes:

Therapeutic response monitoring:

• In lung cancer xenograft models, phospho-BAD (S112/S136) antibodies have revealed that rapamycin treatment enhances BAD phosphorylation at S112 and S136 but not S155

• This differential phosphorylation pattern contributes to rapamycin resistance

• Combined inhibition of S112 and S136 phosphorylation synergistically enhances rapamycin anti-tumor efficacy

Mechanistic investigation approaches:

• Pathway dissection: Use phospho-specific antibodies to identify which upstream kinases (Akt, p90RSK, PKA) are activated in specific cancer contexts

• Temporal dynamics: Monitor phosphorylation changes over time following treatment to identify rapid adaptive responses

• Spatial distribution: Combine with subcellular fractionation to determine compartment-specific phosphorylation patterns

In vivo experimentation strategies:

• For xenograft studies, combine treatments targeting BAD phosphorylation with standard therapies:

  • MEK/ERK inhibitors (e.g., PD98059) to block S112 phosphorylation

  • Akt inhibition via RNAi to prevent S136 phosphorylation

  • Measure tumor volume using the formula V=L×W²/2

Translational research applications:

• Use phospho-BAD immunohistochemistry in patient-derived samples to:

  • Stratify tumors based on phosphorylation profiles

  • Correlate phosphorylation patterns with treatment outcomes

  • Develop predictive biomarkers for targeted therapies

Technical validation for cancer studies:

• For IHC analysis of tumor samples, semi-quantitative evaluation should use immunoscoring based on:

  • Staining intensity (0-4 scale): 0 (none), 1 (weak), 2 (moderate), 3 (strong), 4 (very strong)

  • Percentage of positive cells

  • Combination of both parameters for statistical analysis

These approaches illustrate how phospho-BAD antibodies can bridge molecular signaling analysis with therapeutic outcomes in cancer research, potentially informing personalized medicine approaches .